

Cumulative Index 1996

VOLUME 8

March	THE ELDERLY PATIENT IN CRITICAL CARE, pages 1-106
June	WOUND CARE, pages 107-228
September	LUNG TRANSPLANTATION, pages 229-348
December	CURRENT NURSING ISSUES IN INTRA-AORTIC BALLOON PUMPING, pages 349-503

Note: Page numbers of article titles are in **boldface** type.

- ABI (ankle-brachial index), 132, 134
- Acyclovir, following lung transplantation, 268
- Adverse drug reactions, in the elderly, acute confusion from, 87-88
- drugs with high potential for, 80
- risk factors for, 79-80
- Aerobic exercise, for secretion clearance, 307-308
- Afterload, IABP effect on, 376-378
- Age, skin and, 125-126
- wound healing and, 118-119
- Agitation, physical restraint for, alternatives to, 68
- Air-fluidized mattress, 23-24
- Airway, age-related changes in, 8
- following lung transplantation, anastomosis of, complications of, 275-277
- dehiscence of, 245
- of lung transplantation, clearance of, on ICU, 242-243
- on transplant unit, 247
- Albumin, as monitor of nutritional status, 165-166
- Alginate dressings, 152
- Allografts, for burn wound, 209, 211-212
- Altered body image, 184
- reactions to, defense mechanisms, 188
- depression, 188-189
- grief, 184-188. See also *Grief*.
- postoperative, 189-190
- Alzheimer's disease, sleep and, 43
- Amphotericin B, following lung transplantation, 265
- Ampicillin/sodium sulbactam sodium, following lung transplantation, 264
- Anal sphincter, in fecal continence, 33
- Ankle-arm index. See *Ankle-brachial index (ABI)*.
- Ankle-brachial index (ABI), 132, 134
- calculation of, 474-475
- in vascular assessment, limitation of, 483
- of IABP patient, 481
- versus Doppler velocity detection, 482-483
- versus pulse palpation, 482
- of peripheral vascular perfusion, 474-475
- Antibiotics, characteristics of, 263-264
- following lung transplantation, 262
- Anticholinergics, delirium from, 56
- Anticoagulation, in IABP patient, 391
- Anticonvulsants, in the elderly, for seizures, 73-75
- quality of life and, 76
- Antidiarrheal agents, 37
- Antifungals, characteristics of, 265-267
- following lung transplantation, 262
- Antioxidants, in immunonutrition, 164
- Antivirals, characteristics of, 268-269
- following lung transplantation, 262
- Anxiety, following lung volume reduction surgery, management of, 328-329
- in altered body image, 188
- in emphysema, 324
- organic, from cyclosporine, 288
- posttraumatic in wounding, 190-191
- Aortic pressure, IABC effect on, 377-378
- Arginine, in immunonutrition, 162
- Arrhythmia, in IABP patient, 391
- real-timing IABC in, 358-362
- Arterial pressure waveform, assessment of augmented, timing landmarks in, 349-351
- Arteriosclerosis, sepsis and, 3
- Arthroplasty, hip and knee, 221
- Aspergillus* infections, following lung transplantation, 284
- Assessment of wounds, **125-139**
- Assurance, in critical illness, as family need, 93
- for elderly family member, 97

- ATG (antithymocyte globulin), in lung transplantation, 259
- Atrial fibrillation, following lung volume reduction surgery, 329
- Autografts, 172
cultured epithelial, 211
for burn wound, 207, 210
- Autolysis, of burn wound, 207
of wounds, 147-148
- Azathioprine (Imuran), characteristics of, 257
rejection of lung transplant and, preventive, 255
- Bates-Jensen Pressure Sore Status Tool, 131, 134
- BCCA(s) (leucine, isoleucine, valine), in immunonutrition, 163
- Bead dressings, 152
- Beds, pressure-reducing, 24-25
- Behavior, disruptive, physical restraint and, 65
- Benzodiazepines, in the elderly, for insomnia, 48
for seizures, 75
- Biologic wound covers, 209-212
- Bladder function, physiology of, 29-30
- Bleeding, during IABP, 413-414
retroperitoneal, 414
- Blood pressure, assessment of, in IABC patient with pharmacologic intervention, 398-399
in IABP, versus non-IABP patient, 471-473
in IABP patient, documentation of, 480-481
reference point for titration of vasopressor and vasodilator drugs, 473-474
- Blood supply, in flap grafts, 175, 176
- Body image, altered, 184. See *Altered body image*.
concept of, 183-184
development of, 184
- Body temperature, in the elderly, sepsis and, 3
- Bondville technique, in graft harvest, 172
- Bone marrow suppression, with azathioprine, 288
- Braden Scale for Predicting Pressure Sore Risk, 127-129, 430
- Brain scans, in seizure diagnosis, 73
- Breathing, control of, in the elderly, 11
pursed-lip, following lung volume reduction surgery, 328
- Breathlessness, conditioning and, in lung transplant recipient, 246
- Bronchodilators, following lung volume reduction surgery, 327
- Bronchopulmonary hygiene, for secretion clearance, 308
- Bulking agents, for routine fecal evacuation, 37-38
- Burn wound, care of, allografting in, 209, 211-212
autografting in, 207, 210
autolysis in, 207
biologic and synthetic covers in, 209-212
excision in, 207-208
psychosocial, 213
rehabilitation in, 212-213
skin substitutes in, 211-212
topical antimicrobials for, 207, 209
causes of, 203-204
depth of, 204-206
extent of, 204, 208
first degree, 204, 206
histologic staging of, 205, 207
incidence of, 203
infection of, 205, 207
monitoring of, 205
second degree, 204, 206
third degree, 204, 206
versus surgical wound, 127
zones of, 204, 207
- Calorimetry, in monitoring of nutritional status, 166
- CAM (Confusion Assessment Method), in delirium diagnosis, 57-58
- Candida* species infections, following lung transplantation, 284
- Carbamazepine, for seizures, in the elderly, 74-75
- Carbohydrates, in nutrition support, 161, 164-165
metabolism of, 197
- Cardiac index (CI), in IABP patient with pharmacologic intervention, 402
- Cardiac output (CO), IABC effect on, 379
in IABP patient with pharmacologic intervention, 402
mechanics of, IABC and, 375-379
IABP and, 375-379
- Cardiac surgery patient, intra-aortic balloon pump and, 398
- Cardiology patient, intra-aortic balloon pump and, 397
- Cardiovascular disease, age-related changes in, and sleep, 41-43
- Cardiovascular response, to traumatic wounding, 111
- Cardiovascular studies, in seizure diagnosis, 72
- Cardiovascular system, age-related changes in, sepsis and, 3
wound healing and, 125-126, 134
- CareMap system, as database, 334-335
collaborative group practices and, 333-334
designing of, 336
in discharge process, 340-341
in integration of patient and significant others, 336, 338
in perioperative management, 340
in postoperative phase, 338-340
in pulmonary step down unit, 340
in rehabilitation, after discharge, 338
in week before surgery, 338
preoperative, care coordinators and, 336
initiation of, 336-337
specific patient needs and, 334
- CEA (cultured epithelial autograft), 211
- Cell, injury to, in traumatic wound, 108
- Centers of Excellence, cost-savings with, for transplant recipient, 300-302
- Central nervous system, cyclosporine effects on, 287-288
infection in, seizures following, 72
- Chest physiotherapy, following lung transplantation, 242
following lung volume reduction surgery, 327
- Chest tubes, following lung transplantation, 244
following lung volume reduction surgery, 329
- Chest wall, age-related changes in, 9
- Cheyne-Stokes respiration, sleep and, 42
- Chronic obstructive pulmonary disease (COPD), sleep and, 43-44
- CI (cardiac index), in IABP patient with pharmacologic intervention, 402
- Cigarette smoking, flap graft failure and, 175

- Circulation, pulmonary, age-related changes in, 8
- Circulatory compromise, IABP-related, 416-417
- Cleansing, of wound, 142-143
- wound, 133, 137, 142-143
- Clotrimazole, following lung transplantation, 267
- CLRT (continuous lateral rotation therapy), 432
- CO. See *Cardiac output (CO)*.
- Collaboration, in wound care, 137
- Collateral circulation, IABC effect on, 374
- myocardial oxygen supply and, 371
- Comfort, provision of, for elderly family member, 98-99
- Competence, American Association of Critical Care Nurses and, 441
- in IABP patient care, achievement of, 443-444
- IABP team and, 446-448
- Joint Commission on Accreditation of Healthcare Organizations on, 441-442
- versus competency, 442-443
- Competency, competence versus, 442-443
- in IABC, education for, 462
- in IABP patient care, checklist for, 454
- measurement of, mock run, 443-444
- scenario for, 445-446
- Sharp Healthcare evaluation standards for, 453
- Complement cascade, in wound healing, 116
- Complex-partial seizures, in the elderly, 73
- Complications of intra-aortic balloon pumping, 409-421
- Compression, for ulcers of lower extremity, 154-155
- Confusion Assessment Method (CAM), in delirium diagnosis, 57-58
- Confusional state, drug-induced, 87-88
- in sepsis, 3
- physical restraint for, alternatives to, 68
- Continence management, 29-38. See *Fecal incontinence; Incontinence; Urinary incontinence*.
- Continuous lateral rotation therapy (CLRT), 432
- Continuous positive-airway pressure (CPAP), for obstructive sleep apnea syndrome, 46
- Contractile state, myocardial oxygen consumption and, 372
- Contractility, IABC effect on, 378-379
- indicators of, in IABP patient with pharmacologic intervention, 399-400, 406
- Conventional timing (CT) intra-aortic balloon counterpulsation (IABC), case reports of, 363-364, 366-368
- COPD. See *Chronic obstructive pulmonary disease (COPD)*.
- Coronary flow/velocity, IABC effect on, 373-374
- Coronary perfusion pressure (CPP), in IABP patient with pharmacologic intervention, 399
- Corticosteroids, characteristics of, 257
- rejection of lung transplant and, preventive, 255
- therapeutic, 255-256
- toxicity of, gastrointestinal, 287
- musculoskeletal, 287
- Cost, of IABP community hospital program, 466
- CPAP (continuous positive-airway pressure), for obstructive sleep apnea syndrome, 46
- CPP (coronary perfusion pressure), in IABP patient with pharmacologic intervention, 399
- C-reactive protein, in monitoring of nutritional status, 165
- Critical care units, physical restraints in, 63
- Critical injury, effect on aged family members, 92-93
- family needs following, 93-94
- Cultured epithelial autograft (CEA), 211
- Cyclosporine, characteristics of, 256
- drugs affecting, 254
- rejection of lung transplant and, preventive, 253-255
- therapeutic, 255
- toxicity of, central nervous system, 287-288
- dermal, 288
- renal, 286-287
- Cytokines, in wound healing, 116, 118
- metabolism and, 159
- Cytomegalovirus infection, following lung transplantation, 282-284
- Debridement, in wound management, 133-134, 143-148
- autolytic, 147-149
- chemical, 145-146
- mechanical, 145
- methods of, 148
- sharp surgical, 144-145, 148
- Decision-making, by lung transplant candidate, 294
- Decubitus ulcers. See *Pressure ulcers*.
- Defecation, 33-34
- Defense mechanisms, in altered body image, 188
- posttraumatic wounding, 190
- Deformities, visible, reactions to, 191-192
- Degloving injury, skin grafting in, 172
- Dehiscence, in arthroplasty wounds, 221
- of sternotomy wound, 220-221
- of surgical wound, 140
- Delirium, diagnosis of, 54
- Confusion Assessment Method in, 57-58
- differential diagnosis of, 54-55
- in the hospitalized elderly, 53-60
- adverse effects of, 53
- definition of, 54-55
- incidence and prevalence of, 53
- management of, 57-58
- problem of, 53-54
- risk factors for, 55-57
- versus dementia, 54-55
- Dementia, delirium versus, 54-55
- sleep and, 43
- Denial, in lung transplant candidates, 294
- of altered body image, 188
- Depression, in loss of body part or function, 188-189
- major, criteria for, 189
- Dermis, 126
- Detrusor muscles, in bladder function, 30
- Diabetes mellitus, and wound healing, 119-120, 195-201
- assessment in, 199
- factors affecting, 197-198
- monitoring of, 199-200
- patient education for, 200
- classification of, 195-196
- incidence of, 195
- pathophysiology of, 197
- type I, 196
- type II, 196
- wound healing and, 130

- Diaphragmatic hernia, following lung transplantation, 277
- Diarrhea, fecal incontinence from, 34
- skin breakdown from, 26, 37
- Diastolic blood pressure, augmentation with IABP, decrease in, 475
- Diastolic pressure augmentation, with intra-aortic balloon pumping, factors affecting, 351
- with intra-aortic balloon pumping, 396
- decrease in, 475
- factors affecting, 351
- Diastolic pressure-time index (DPTI), in IABC and myocardial oxygen consumption, 374
- Diazepam, for status epilepticus, 75
- Diffusion capacity, in the elderly, 10-11
- Discharge planning, following lung transplantation, 299-300
- teaching in, 249-251
- following lung volume reduction surgery, 329-330
- of lung reduction surgery patient, CareMap system in, 340-341
- Dissection of the aorta, IABP-related, 416
- Dobutamine, in IABP patient, 393
- blood pressure and titration of, 473
- Dobutamine plus dopamine, with IABP, for left ventricular failure, 396
- Dobutamine plus nitroglycerin, with IABP, for left ventricular failure, 396
- Dobutamine plus nitroprusside, with IABP, for left ventricular failure, 396
- Donor, criteria for, in living related donor program, 236
- in lung transplantation, 232-233
- death of, transplant recipient emotions and, 297-298
- Donor sites, for skin grafts, dressings for, 208, 210
- Dopamine, in IABP patient, 393
- blood pressure and titration of, 473-474
- Dopamine plus nitroprusside, with IABP, for left ventricular failure, 396
- Doppler ultrasonography, for arterial patency, 180
- DPTI (diastolic pressure-time index), in IABC and myocardial oxygen consumption, 374
- Dressings, for moist environment, 148
- for skin graft donor sites, 208, 210
- purpose of, 148-149
- selection of, 144-152
- types of, 149-152
- alginate, 152
- foam, 152
- gauze, 149-151
- gels/hydrogels, 151-152
- hydrocolloids, 151
- pastes, powders, beads, 152
- polyurethane film, 151
- Drug, in the elderly, absorption of, 80-82
- distribution of, 82
- metabolism of, 82-83
- renal excretion of, 83
- Drug interactions, in the elderly, case example of, 86-87
- Dying patient, skin breakdown in, 27
- Dyspnea, following lung volume reduction surgery, management of, 328
- in emphysema, 324
- in the elderly, in weaning failure, 13-14
- sensation of, 11-12
- Ebb phase, in wound healing, 109-110
- Edema, pulmonary, following lung transplantation, 241, 243
- EEG (electroencephalogram), in seizure diagnosis, 72-73
- EF. See *Ejection fraction (EF)*.
- Ejection fraction (EF), IABC effect on, 379
- in IABP patient with pharmacologic intervention, 402
- EKG (electrocardiogram), in seizure diagnosis, 72
- Elderly family members, of critically ill person
- assessment of, 94-97
- assurance for, 97
- comfort of, 98-99
- comparison with younger members, 92
- contact with, initial, 94-95
- critical injury effect on, 92-93
- evaluation of, 99-100
- family database and, 95-97
- goals of, 93-94
- information management and, 98
- interventions with, 97-99
- needs of, 93-94
- orientation to critical care and, 97
- other family members and, 95-96
- role of, 96
- spokesperson for treatment plans and, 96-97
- support of, 99
- understanding goals of, 93-94
- visitation and, 97-98
- Electrocardiogram (EKG), in seizure diagnosis, 72
- Electroencephalogram (EEG), in seizure diagnosis, 72-73
- Embolus, helium, 410
- with IABP, 417-418
- Emotional support, for transplant recipient and family, 248
- Emotions, in emphysema, 324
- of lung transplant recipient, 298-299
- Emphysema, air trapping in, 323-324
- definition of, 323
- emotions in, 324
- hyperinflation in, 324
- lung transplantation for, 324-325
- lung volume reduction for, history of, 324
- treatment of, 324
- Empyema, postpneumectomy, musculoskeletal flaps for, 176-177
- Endocardial viability ratio (EVR), in measurement of myocardial oxygen consumption, IABC and, 374-375
- Endotracheal intubation, physical restraint and, 65
- Endotracheal suctioning, following lung transplantation, 242
- Enteral feeding, of lung transplant recipient, 245-246
- Enteral nutrition, in acute illness and wounding, 160-161
- advantages of, 161
- Environmental Protection Agency (EPA), patient medical waste management and, 222
- Enzymes, for debridement, 145-147
- EPA (Environmental Protection Agency), patient medical waste management and, 222
- Epidermis, 125-126
- Epigastric pain, sleep and, 44
- Epinephrine, in IABP patient, 393

- Epstein-Barr virus infection, following lung transplantation, 284
- Erythromycin, following lung transplantation, 264
- Essential nutrients, for wound healing, 161-162, 164-165
- Ethical issues, physical restraint and, 65
- EVR (endocardial viability ratio), in measurement of myocardial oxygen consumption, IABC and, 374-375
- Excision, in burn wound care, 207-208
of burn wound, 207-208
- Exercise, for lung transplant recipient, predischARGE teaching and, 249
- Exercise conditioning, adjuncts to, 313-317
ambulation and, 313, 316
basic techniques, 309, 312-313
fundamentals of, 312
in pulmonary surgery, **305-322**
hypotheses and effects of, 306-309
parasympathetic activity and, 308
patient compliance/motivation, 309
secretion clearance and, 307-308
skeletal muscle performance and, 306-307
vascular resistance and, 308-309
limitations in, minimization of, 309, 312
Massachusetts General Hospital program for, 321-322
oxygen and, 313, 316, 317
stationary bicycle ergometry and, 313, 316
ventilatory muscle training and, 313-315
- Extracorporeal circulation, pressure ulcer risk with, 424
- Extraurethral incontinence, 32
- Face, disfigurement of, 191-192
- Failure to wean, age-related pulmonary changes and, **7-16**
anatomic and physiologic, 7-10
nursing role in, 8
pulmonary function and, 10-11
respiratory failure and, 12-14
ventilatory perfusion and gas exchange and, 11-12
- Falls, prevention of, physical restraint for, 64
versus physical restraint, 67
risk of, with physical restraint, 63
- Family, education of, in surgical incision care, 142
in wound care planning, 137
of lung transplant recipient, emotions of, 248
predischARGE teaching for, 249-251
- Family members, aged, **91-102**. See *Elderly family members*.
of elderly, with sepsis, 5-6
teaching needs of, in seizures in the elderly, 76-77
- Fat, in nutrition support, 161-162, 164-165
metabolism of, in diabetes mellitus, 197
- Fears, of lung transplant candidates, 294-295
of lung transplant recipient, 299-300
- Fecal incontinence, acute/transient, 34-35
chronic, 34
continence and, physiology of, 32-34
management of, 37-38
pathophysiology of, 34
skin breakdown from, 26-27
perianal pouches for, 27
rectal catheters for, 27
- Femoral artery damage, in IABP, bleeding from, 413
- FEV₁ (forced expiratory volume), in the elderly, 10
- Financing, of lung transplantation, 300-302
- FK506 (tacrolimus), characteristics of, 262
rejection of lung transplant and, therapeutic, 259
- Flap graft(s), axial pattern, 175
classification of, 174
failure of, 175
free, 178-181
groin, 175
musculocutaneous, 176-178
random pattern, 174
survival of, 175-176
types of, 174-175
uses of, 174
- Flow phase, in wound healing, 110
- Flucytosine, following lung transplantation, 265
- Fluid resuscitation, in sepsis, 4
- Fluid status, in IABP patient with pharmacologic intervention, left heart, 401-402
right heart, 401
in traumatic wounding, 112
indicators of, in IABP patient with pharmacologic intervention, 401-402, 406
of lung transplant recipient, on ICU, 243-244
on transplant unit, 247
- Fluid therapy, in IABP patient, 392-393
- Foam dressings, 152
- Forced expiratory volume (FEV₁), in the elderly, 10
- Forced vital capacity (FVC), in the elderly, 10
- Foscarnet, following lung transplantation, 269
- Fractures, from physical restraint, 64
- Free flaps, advantages of, 179
donor sites for, 178
failure of, 180
nursing aspects of, 180
postoperative monitoring of, 180-181
preoperative factors and, 179-180
uses of, 178-179
- Functional urinary incontinence, 32
- FVC (forced vital capacity), in the elderly, 10
- Ganciclovir, following lung transplantation, 268
- Gas exchange, in the elderly, 11
- Gauze dressings, 149
continuously moist, 150-151
dry, 150
set-to-dry, 150
- Gel dressings, 151-152
- Glucose, metabolism of, in diabetes mellitus, 195-197
- Glutamine, in immunonutrition, 162-163
- Glycemic control, in diabetes mellitus, 197, 200
- Grief, as reaction to acute wounding, 184-188
models of, 185-187
- Growth hormone, wound healing and, 116, 164-165
- Hand injury, traumatic, 190
- Harper Skin/Wound Care Protocol, 143-150
- HBO (hyperbaric oxygen), in flap grafts, 176
- Heart rate, age-related changes in, and sleep, 41-42
IABC effect on, 379
myocardial oxygen consumption and, 372

- Hemodynamic concepts, cardiac output, mechanics of,
IABC and, 375-379
myocardial oxygen consumption, 372-373
IABC and, effects on, 373-374
measurement of, 374-375
myocardial oxygen supply, 371-372
understanding advanced, **371-381**
- Hemodynamic profiling, in IABP patient with
pharmacologic intervention, 402-406
- Hemodynamic status, following lung transplantation,
277
of lung transplant recipient, on ICU, 243
on transplant unit, 247
- Hemorrhage, following lung transplantation, 275
- Hemostasis, in traumatic wound, 107-108
- Herpes simplex virus infections, following lung
transplantation, 284
- Hydration, in sepsis, 3-4
- Hydrocolloid dressings, 151
- Hydrogel dressings, 151-152
- Hyperbaric oxygen (HBO), in flap grafts, 176
- Hypercholesterolemia, with corticosteroid therapy, 288
- Hyperglycemia, with corticosteroid therapy, 288
- Hypertension, pulmonary, exercise effects on, 310-311
post-lung transplantation, 244
- Hypoglycemics, in diabetes mellitus, 199
- Hypotension, following lung transplantation, 243, 277
- Hypoxemia, following lung transplantation, 244
- IAB. See *Intra-aortic balloon (IAB)*.
- IABC. See *Intra-aortic balloon counterpulsation (IABC)*.
- IABP. See *Intra-aortic balloon pump (IABP)*; *Intra-aortic balloon pumping (IABP)*.
- Ileus, adynamic, following lung transplantation, 277
- Immobilization, pressure ulcer risk with, 424
- Immune response, to traumatic wounding, 111
- Immunoincompetence, wound healing and, 115,
121-122
- Immunonutrition, components of, 162-164
- Immunosuppressants, toxicities of, 286-288
central nervous system, 287-288
dermal, 288
endocrine, 288
gastrointestinal, 287
hematologic, 288
musculoskeletal, 287
psychiatric, 288
renal, 286-287
- Imuran. See *Azathioprine (Imuran)*.
- Incision(s), closed, wound care products for, 141-142,
145
open, wound care products for, 142, 145
- Incontinence. See *Fecal incontinence*; *Urinary incontinence*.
fecal, 32-35, 37-38
fecal or urinary, wound healing and, 131
skin breakdown from, 26-27
urinary, 31-32, 35-36
- Infection, following lung transplantation, medications
for, 259-269
predischARGE teaching and, 250-251
prevention of, 285
recipient fear of, 299-300
from IABP catheter, 14
nosocomial, postoperative, 219-220
of burn wound, 205, 209
of pressure ulcers, 25-26
of sternotomy wounds, 177
prevention of, in traumatic wounding, 112
wound healing and, 116, 121
- Inflammation, after traumatic wounding, 108-109
in wound healing, 115, 116-117, 130
- Information, provision of, to elderly family member, 98
- Injury, cellular, in traumatic wound, 108
- Inotropic therapy, in IABP patient, 393-394
in sepsis, 4
- Instability incontinence, 32
- Insulin therapy, in diabetes mellitus, 196
types of, 199-200
- Interference with treatment, physical restraint and,
alternatives to, 67
for prevention, 64
- Interventions for aged family members, **91-102**. See
Elderly family members.
- Intestinal transit time, fecal continence and, 32-33
- Intra-aortic balloon counterpulsation (IABC), clinical
observations with real timing in, **357-370**. See
Real-timing (RT) Intra-aortic balloon counterpulsation (IABC).
developing and implementing a standard of care for,
451-457
development process in, 452-453
format for, 452
Sharp Healthcare standards, 453
standards in, derivation of, 452
versus guidelines, 451-452
education and competency in, 462
hemodynamic effects of, metabolic, 379
nursing implications of, 380
renal and cerebral flow, 379-380
management issues in, committee development,
469-4460
console selection, 460-461
critical care staff involvement in, 461-462
fiscal considerations in, 462
standard of care for, evaluation of, 456-457
Quality Assessment Monitor in, 456-457
implementation of, 454-456
compliance with, 455-456
development of, 452-454
education for, 454-455
timing in, case reports of real and conventional,
363-364, 366-368
case reports of real and conventional timing in,
363-364, 366-368
- Intra-aortic balloon (IAB), circulatory compromise
from, 414-415
entrapment of, 415-416
malposition of, 414
migration of, 414-415
rupture of, 414-415
- Intra-aortic balloon (IAB) catheter, restriction of,
385-386
causes of, 385-386
troubleshooting of, 385-386
- Intra-aortic balloon (IAB) catheter, removal of,
483-484
- Intra-aortic balloon (IAB)-pressure waveforms,
correlation to troubleshooting gas leakage and
restriction alarms, **383-388**
in catheter restriction alarm, 385-386

- in gas-leakage alarm, 386-387
 - causes of, 386-387
 - interventions in, 387
 - normal, segments of, 384
 - use of, 383
- Intra-aortic balloon pump (IABP), effectiveness of,
 - factors influencing, 397
 - issues from a management perspective, **459-463**
 - physiologic action of, 396
 - practice change in, research model for, 485-486
 - removal of, 418
 - selection of, critical care staff involvement in,
 - 461-462
 - fiscal considerations in, 462
 - for community hospital program, 466, 468
 - training in, 454-455, 462, 468
 - basic course content for, 449
 - clinical skills competence test in, 449
 - refresher course content, 450
 - uses of, 465-466
- Intra-aortic balloon pump (IABP) patient,
 - augmentation of diastolic pressure in, 396
 - cardiology and cardiac surgery, 397-398
- care of, **471-476**
 - ankle/arm index computation in, 474-475
 - blood pressure in, 471-473
 - competence in, 443-448
 - diastolic augmentation decrease, factors in, 475
 - mean arterial pressure calculation in, 471-473
 - pressure reference point for vasopressor and vasodilator drips, 473-474
 - roles and responsibilities in, 484-485
 - diastolic pressure augmentation in, 396
 - drug therapy and IABP for, hemodynamic assessment of, 398-402
 - summary of hemodynamic effects with, 395
 - fluid therapy in, 392-393
 - hemodynamic assessment of, 398-402
 - acceleration time in, 400-401
 - blood pressure in, 398-399
 - indicators in, of contractility, 399-400
 - of fluid status, 401-402
 - of oxygenation, 401
 - of perfusion, 398-399
 - of vascular status, 400-401
 - mean arterial pressure in, 398
 - hemodynamic profiling of, 402-406
 - case history, 402-406
 - hemodynamic status of, overview of, 401
 - IABP in, hemodynamic effects of, 396
 - physiologic action of, 396-397
 - management of, **389-408**
 - arrhythmias in, 391
 - general considerations for, 390-391
 - pain in, 391
 - sedation, 391
 - mechanical unloading in, 397
 - oxygenation and metabolic problems in, 391-392
 - pharmacologic considerations, combination drug therapy in, 394-395
 - inotropic therapy in, 393-394
 - vasoactive drug therapy in, 393
 - vasoconstrictors, 394
 - vasodilators, 394
 - pharmacologic management of, anticoagulation in,
 - 391
 - for pain, 391
 - preload in, optimization of, 392-393
- Intra-aortic balloon pump (IABP) patient care,
 - competence and competency in, **441-450**
- Intra-aortic balloon pump (IABP) team, competence
 - and competency and, 446-448
 - direct bedside provider on, certification of, 448
 - first responder role on, 447-448
 - in IABP program design, 462
 - medical director responsibilities on, 447
 - nursing coordinator on, 447
 - physician insertion certification and, 447
- Intra-aortic balloon pumping (IABP), arterial blood
 - pressure assessment in, 354-355
 - arterial pressure in, assessment of, 349-351, 354-355
 - increased, 354
 - arterial pressure increase in, 354
 - balloon in, filling gas in, 354
 - position of, 353-354
 - size/volume/occlusivity of, 353
 - community hospital program for, case example,
 - 469-470
 - development of, cost in, 466
 - need justification in, 466
 - policies and procedures development in, 468
 - pump selection in, 466, 468
 - training in, 468
 - pump selection in, 466, 468
 - review of 5-year experience, 467-468
- complications of, **409-421**
 - balloon entrapment, 415-416
 - balloon rupture, 414-415
 - bleeding problems, 413-414
 - compromised circulation, 416-417
 - dissection of aorta during, 416
 - incidence of, 409
 - infection, 414
 - limb ischemia, 411-413
 - obstruction, from plaque or emboli, 417-418
 - prevention of, 411-418
 - risk factors for, 411
- current practice issues in, **477-490**
 - identification of, 478
 - impact of technology, 478-479
 - historical trends and, 479
 - patient assessment and, 479-480
 - technology assessment and, 479
- current practice survey, anecdotal responses to,
 - 489-490
 - catheter removal and hemostasis, 483-484
 - demographics of, 480
 - development of research model and, 485-486
 - hemodynamic parameters in, 481-482, 488
 - IABP blood pressure documentation in, 480-481
 - qualitative data analysis in, 484-485
 - results of, 480-485
 - roles and responsibilities in, 483-484
 - vascular assessment in, 481-483
- in the community hospital setting, **465-470**
 - indications for, 410-411
 - mortality rate reduction with, 465-466
 - pump example in, 410
 - theory versus research in, 479
 - timing in, conventional versus real time in, 351
 - deflation, 351, 353, 355
 - inflation, 351-352
- Irrigation, of wound, 143

Isoleucine, in immunonutrition, 163
 Isoproterenol, in IABP patient, 394

Keratinocytes, cultured, 211-212
 Ketoconazole, following lung transplantation, 266
 Kinin cascade, in wound healing, 116

Lateral rotation bed, 24
 Left ventricular end-diastolic pressure (LVEDP), in
 IABP patient with pharmacologic intervention, 401
 Left ventricular power failure, cardiovascular drug-
 IABP management of, 392-396
 combination pharmacotherapy with IABP, 394-395
 combination pharmacotherapy with IABP for, 394,
 396
 hemodynamic profile of, 389-390
 IABP in, physiologic action of, 396-397
 physiology of, 389-390
 predictors of clinical outcome in, 390-391
 Left ventricular stroke work index (LVSWI), in IABP
 patient with pharmacologic intervention, 400
 Left ventricular work, IABC effect on, 378
 Leg defects, graft reconstruction of, 177-178
 Leucine, in immunonutrition, 163
 Liability, prevention of, physical restraint and, 65
 Lifestyle, predischARGE teaching and, for lung
 transplant recipient, 251
 Limb ischemia, definition of, 411-412
 from IABP, causes of, 411-412
 prevention of, 412-413
 treatment of, 413
 Living related donor (LRD) transplants, 235-236, 302
 Lorazepam, for status epilepticus, 75
 Low air-loss beds, 23-24
 for pressure ulcer prophylaxis, 425-426
 rental cost of, 425, 430
 versus standard bed, for pressure ulcer prophylaxis,
 429-438
 versus standard beds, for pressure ulcer prophylaxis,
 426
 LRVS. See *Lung volume reduction surgery (LRVS)*.
 Lung, age-related changes in, 8-9
 volume and capacities of, in the elderly, 10
 Lung transplant recipient, postoperative care of,
 positioning in, 241-242
 rehabilitation in ICU, 245-246
 transfer of, to transplant unit, 246-248
 transition to ICU and, 239-245
 airway clearance and, 242-243
 hemodynamic and fluid status in, 243-245
 oxygenation in, 240-242
 team in, 239-240
 Lung transplantation. See *Lung volume reduction
 surgery (LRVS)*.
 assessment for, functional and physical, 305-306
 complications following, **273-292**
 abdominal, 244
 from surgery, 273, 275-278
 immunosuppressant toxicities, 286-288
 infections, 282-285
 malignancies, 285-286
 rejection, 278-282
 timing of, 274

contraindications to, 231, 295
 donor in, criteria for, 232-233
 recipient issues and, 298-299
 financing of, 300-302
 Center of Excellence and, 300-302
 follow-up in, long-term, 233-234
 history of, 229-230
 immunosuppressive therapy following, 253-255
 azathioprine, 255
 corticosteroids, 255
 cyclosporine in, 253-255
 OKT3, 255
 indications for, 230-232
 infections following, bacterial pneumonia, 282-283
 cytomegalovirus, 283-284
 Epstein-Barr virus, 284
 fungal, 284
 herpes simplex virus, 284
 mycobacterial, 284-285
 pharmacotherapy for, 259-269
Pneumocystis carinii pneumonia, 284
 prevention of, 285
 respiratory syncytial virus, 284
 living related lobe donation in, 235-236
 medications following, **253-271**
 outcomes of, 235
 overview of, **229-238**
 postoperative care in, **239-252**
 preoperative and postoperative conditioning for,
305-322. See *Exercise conditioning, in
 pulmonary surgery*.
 psychosocial and financial aspects of, **293-303**
 psychosocial aspects of, 293-300
 discharge and normalizing, 299-300
 evaluation for, 292
 news of and decision for, 294-295
 transplantation, 299
 wait for, 295-298
 recipient in. See *Lung transplant recipient*.
 criteria for, 230
 evaluation of, 231-232
 postoperative care of, 239-252
 selection of, 230-232
 rejection following, pharmacotherapy for, 255-259
 prevention of, 253-255
 surgical technique in, 232-233
 teams in, 240, 333
 transplant medications in, **253-271**
 wait for, emotional issues in, 297-298
 hospitalizations during, 297
 loss of control during, 296-297
 orientation program in, 296
 patient responsibilities in, 296
 Lung Volume Reduction Surgery Collaborative Group
 Practice, CareMap program development and,
 333-334
 CareMap system in, 334-342. See *CareMap
 system*.
 formulation of patient flow in, 333-334
 Lung volume reduction surgery (LRVS), assessment for,
 functional and physical, 305-306
 bilateral, procedure for, 325
 CareMap for, **333-343**
 conditioning for, preoperative and postoperative,
305-322
 contraindications to, 309

- discharge planning and, 329-330
for emphysema, **323-331**. See *Emphysema*.
patient in, compliance/motivation of, 309
selection criteria for, 325-326
postoperative care and, cardiovascular function in, 329
chest tubes in, 329
for anxiety, 328-329
for dyspnea, 318
nutrition in, 329
pain management in, 328
respiratory management in, 327
preparation for, 327
LVEDP (left ventricular end-diastolic pressure), in IABP patient with pharmacologic intervention, 401
LWSWI (left ventricular stroke work index), in IABP patient with pharmacologic intervention, 400
- Macrophages, in wound healing, 117
Malnutrition, in lung transplant recipient, 245-246
wound healing and, 120-121, 130, 198
Mattresses, pressure-reducing, 22-24
Mean arterial pressure (MAP), assessment of, in IABC patient with pharmacologic intervention, 398
in IABP versus non-IABP patient, 472-473
Mechanical ventilation, failure to wean from. See *Failure to wean*.
in sepsis, 5
Medical waste management, in home wound care, 221-222
Medications, delirium from, 56
effect of, on skin, 19-21
on sleep, 44-45
in lung transplantation, antibiotics, 262
antifungals, 262
antivirals, 262
ATG, 259
azathioprine, 255, 257
characteristics of, 256-258, 260-261
corticosteroids, 255, 257, 259
cyclosporine, 253-256
for infection, 259-270
for rejection, 253-259
nitric oxide, 262, 270
OKT3 (muromonab-CD3), 255, 258
predischarge teaching and, 249
tacrolimus, 259
osmotic diarrhea from, 34
urinary incontinence from, 31
Mental status, in delirium, 55
in sepsis, 3
Metabolism, cytokines and, 159
in stress versus starvation, 159-160
of carbohydrates, 197
of fat, 197
of glucose, 195-197
of protein, 197
Miconazole, following lung transplantation, 266
Minerals, in nutrition support, 162, 164-165
Minitracheostomy, following lung volume reduction surgery, 327-328
Muromonab-CD3. See *OKT3 (muromonab-CD3)*.
Muscle shortening, myocardial oxygen consumption and, 372
Muscles, in musculocutaneous flaps, 176
Musculocutaneous flaps, nursing aspects of, 178
uses of, 176-177
Mycobacterium tuberculosis, following lung transplantation, 284-285
Myocardial infarction, circadian pattern in, 42
drug-related complications of, in the elderly, 86-87
following lung transplantation, 277
Myocardial oxygen consumption (MVO₂), determinants of, 372
IABP effect on, 373-374
in IABP patient with pharmacologic intervention, 402
measurement of, 372-373
IABP and, 374-375
Myocardial oxygen delivery (MDO₂), in IABP patient with pharmacologic intervention, 402
Myocardial oxygen demand (MVO₂), in IABP patient with pharmacologic intervention, 399
Myocardial oxygen supply (MSO₂)
collateral circulation, 371
coronary blood flow control, 371-372
- Nephrotoxicity, of cyclosporine, 286-287
Nervous system, age-related changes in, and sleep, 40-41
Neuropathy, fecal incontinence from, 35
Nicotine, flap graft failure and, 175
Nitric oxide, following lung transplantation, 244, 262
Nitrogen base studies, in monitoring of nutritional status, 166
Nitroprusside, in IABP patient, blood pressure and titration of, 474
Norepinephrine, in IABP patient, 393
Nucleotides, in immunonutrition, 163
Nursing homes, physical restraints in, 62-63
Nutrition, following lung transplant recipient, predischarge teaching and, 249-250
following lung transplantation, 245
following lung volume reduction surgery, 329
in sepsis, 3, 5
in traumatic wounding, 112
in wound dehiscence, 221
in wound healing, 131
skin breakdown and, 19, 21-23
Nutrition support, essential nutrients in, 161-162, 164-165
in acute illness and wounds, **159-167**
components of, 161-162
enteral, 160-161
goals of, 159
immunonutrition in, 162-164
initiation of, 160
monitoring of, 165-166
parenteral, 160
in wound care, 135
Nystatin, following lung transplantation, 267
- Obesity, wound healing and, 120
Obstructive sleep apnea (OSA) syndrome, cardiopulmonary effects of, 44-45
definition of, 44
prevalence of, 45-46
treatment of, 46

- OKT3 (muromonab-CD3), characteristics of, 258
rejection of lung transplant and, preventive, 255
Omega-6 polyunsaturated fatty acids (PUFA), in immunonutrition, 163-164
OSA. See *Obstructive sleep apnea (OSA) syndrome*.
Osmotic diarrhea, fecal incontinence from, 34
Osteoporosis, corticosteroid-induced, 287
Overflow incontinence, 32
Oxygen balance, wound healing and, 119
Oxygen consumption (VO_2), lung surgery success and, 305
Oxygenation, of lung transplant recipient, in ICU, 240-242
 on transplant unit, 247
Oxygenation and metabolic problems, in IABP patient, 391-392
- Packed cells, in sepsis, 4-5
Pain, skin breakdown and, 21-22
 sleep and, 44
Pain control, following lung volume reduction surgery, 328
 in lung transplant recipient, on ICU, 245
 on transplant unit, 247-248
 in wound care, 135
Pain management, in IABP patient, 391
Parasympathetic activity, exercise conditioning effect on, 308
Parenteral nutrition, in acute illness and wounding, 160
Parkinson's disease, sleep and, 43
Paste dressings, 152
Patient education, in surgical incision care, 142
Patient education, in seizures in the elderly, 76-77
Patient Identification for Rotational Therapy (PIRT), 429, 432
 in cardiovascular surgical patient with IABP support, 429, 432
Pectoralis muscle flap, 177
Pelvic-floor muscles, in bladder function, 31
Perception, disturbance in, in delirium, 54-55
Perfusion, indicators of, in IABP patient with pharmacologic intervention, 398-399, 406
 peripheral vascular, 474-475
Perianal pouches, for fecal incontinence, 27, 37
Periodic limb movements of sleep (PLMS), 46
Peripheral vascular perfusion, assessment of, ankle/arm index in, 474-475
Peripheral vascular resistance (PVR), IABC effect on, 378
Pharmacodynamics, in the elderly, 80-81
 changes in, 83-84
Pharmacokinetic and pharmacodynamic monitoring, of elderly in critical care, **79-89**
 adverse reactions and, 85-86
 clinical application of, 84-85
 confusional states and, 87-88
 drug interactions and, 86-87
 pharmacodynamics in, 83-84
 pharmacokinetics in, 80-83
 pharmacologic considerations in, 80
 polypharmacy and, 84-85
Pharmacokinetics, in the elderly, 80-81
 age- and disease-related effect on, 85-86
Pharmacotherapy, for wound healing, 120
 in flap grafts, 176
 in IABP patient care, 392-406. See *Intra-aortic balloon pump (IABP) patient, pharmacologic considerations*.
Phenobarbital, in the elderly, 75
Phenytoin, for seizures, in the elderly, 74
Phosphodiesterase inhibitors, in IABP patient, 394
Photophthomography, in free flap graft monitoring, 181
Physical restraint, current use of, in acute care, 63
 in nursing homes, 62-63
 historic perspective of, 62
 of elderly in critical care, **61-70**
 alternatives to, 66-68
 guidelines for, 66
 reasons for, 63-64
 risks with, 63-64
 versus benefit, 64-65
 skin breakdown from, 22
 staffing and, 65-66
PIRT (Patient Identification for Rotational Therapy [PIRT]), in cardiovascular patient with IABP support, 429, 432
Plastic surgery. See *Flap graft(s); Skin graft(s)*.
 indications for, 169
 planning for, 169-170
PMLS (periodic limb movements of sleep), 46
Pneumocystis carinii pneumonia, following lung transplantation, 284
Pneumonia, following lung transplantation, bacterial, 282-283
 Pneumocystis carinii, 284
Polypharmacy, in the elderly, case example of, 84-85
Polyurethane film dressing, 151
Positioning, of IABP, diastolic augmentation decrease and, 475
 postoperative, of lung transplant recipient, 241-242
Post-transplant lymphoproliferative disorders (PTLDs), following lung transplantation, 286
Posttraumatic stress disorder (PTSD), flashbacks in, 190-191
 from traumatic wounding, 190-191
 criteria for, 191
Powder dressings, 152
Preload, IABP effect on, 375-377
 optimization of, in IABP patient, 392-393
Pressure ulcers. See *Ulcer(s)*.
 assessment of, 127-129, 131-134, 147
 causes of, 126-127, 135, 155, 423-424
 perfusion alterations, 424
 classification of, 425
 definition of, 426
 dressing selection for, 147
 in cardiovascular surgical patients, 423-424
 in cardiovascular surgical patients with IABP support, postoperative management protocol for, 425-426
 study of, 429-438
 findings in, 434-437
 instruments in, 430, 432
 statistical analyses in, 432-433
 variables in, 431-434
 incidence of, 127
 infection of, 25-26
 inverse time-pressure theory of, 423

- pathogenesis of, 426-428
 patients at risk for, 423-424, 428
 predictive variables and, literature review of, 428-429
 risk for, 126-127
 support surfaces for, low air-loss beds, 425-426, 429-438
 specialty, 155-157
 wound care flow chart for, 147
 Pressure-rate product, of myocardial oxygen consumption, 373
 Primary intention healing, 115
 nursing aspects of, 170, 172
 techniques for, 170-171
 Prinzmetal's angina, circadian pattern in, 42
 Proliferation phase, in wound healing, 116, 117, 130-131
 after traumatic wounding, 109
 Protein, in nutrition support, 161, 164-165
 metabolism of, in diabetic mellitus, 197
 wound healing and, 198
 PTSD. See *Posttraumatic stress disorder (PTSD)*.
 PUFA (polyunsaturated fatty acids), in immunonutrition, 163-164
 Pulmonary circulation, age-related changes in, 8
 Pulmonary function, age-related changes in, 10-11
 Pulse oximetry, in free flap graft monitoring, 181
 Pulse rate, in IABP patient with pharmacologic intervention, 399
- Quality assessment, of IABC patient care, 456-457
 Quality of life, seizures in the elderly and, 75-77
- Radiation, wound healing and, 121
 Real timing (RT), mechanism of, 357
 versus conventional timing, 357
 Real timing (RT) intra-aortic balloon counterpulsation (IABC), arterial pressure waveform analysis in, 359-360, 362-364
 landmarks for, 359
 arterial wave pressure analysis in, 359-360, 362-364
 landmarks for, 359
 case reports of, 363-364, 366-368
 clinical observations of, in arrhythmias, 358-362
 inflation effects in, extended duration of, 360-361, 365
 instrumentation in, 358
 late deflation indicators in, 361, 363, 366
 literature review of, 357-358
 Rectal catheters, for fecal incontinence, 27, 37
 Rectal compliance, fecal incontinence and, 35
 Rehabilitation, in burn wound care, 212-213
 of lung reduction surgery patient, CareMap system in, 338
 of lung transplant recipient, in ICU, 245-246
 pulmonary, Massachusetts General Hospital program for, 321-322
 Reimplantation response, following lung transplantation, 275-276
 Rejection, fear of, 299-300
 of lung transplant, 278-282
 acute, 278-280
 chronic, 280-281
 hyperacute, 278
 pharmacotherapy for, 253-259
 predischage teaching and, 251
 prevention of, 281-282
 treatment of, 282
 treatment plan for, 259
 Relaxation techniques, for sleep promotion, 48-49
 Remodeling, after traumatic wounding, 109
 in wound healing, 116, 118, 131
 Renal excretion, of drug, in the elderly, 83
 Renal function, impairment of, with cyclosporine, 286-287
 Renal response, to traumatic wounding, 111
 Respiratory failure, hypoxemic, weaning failure and, 12
 weaning and age and, 12-13
 Respiratory muscles, age-related changes in, 9-10
 Respiratory response, to traumatic wounding, 111
 Respiratory syncytial virus, following lung transplantation, 284
 Respiratory system, age-related changes in, and failure to wean, 7-10
 sepsis and, 3
 Ribavirin, following lung transplantation, 269
 RT. See *Real-timing (RT)*.
 Rule of nines, in burn assessment, 204
- Saline, isotonic, for wound irrigation, 143
 Secondary intention healing, 170
 nursing aspects of, 170
 of wounds, 115
 Secretion clearance, success of pulmonary surgery and, 307-308
 Sedation, in IABP patient, 391
 Sedative-hypnotics, delirium from, 56
 Seizures, in the elderly, **71-78**
 anticonvulsants for, 73-75
 causes of, 71-72
 diagnosis of, 72-73
 incidence of, 71
 prognosis and, 77
 quality of life and, 75-77
 treatment of, 73-77
 types of, 73
 Sepsis, in the elderly, **1-6**
 assessment findings in, 3-4
 cascade response to, 2
 definitions and, 1-2
 family members and, 5-6
 management of, 4-6
 prevention of, 4
 risk factors for, 2-3
 septic shock and, 1
 systemic inflammatory response syndrome and, 1
 SIRS (systemic inflammatory response syndrome), in septic shock, 1
 Skeletal muscle performance, effect on pulmonary surgery outcome, 306-307
 Skin, aging and, 125-126
 layers of, 125-126
 loose stool effect on, 21-22
 management of, 22
 of elderly patients, age-related changes in, 17-19
 breakdown of, 22

Skin (*Continued*)

- dying process and, 27
- incontinence and, 26-27
- infection and, 25-26
- mattresses or beds and, 22-25
- medications and, 19-20
- nutrition and, 19, 21-23
- pain and, 21-22
- protection of on intensive care unit, **17-28**
- sepsis risk and, 2
- oxygen and nutrient delivery to, medication effect on, 19-21
- Skin breakdown, in the elderly, from incontinence, 26-27
 - restraints and, 22
 - risk factors for, 17-19, 22
- Skin care flow chart, 144
- Skin graft(s), appearance of healed, 173
 - banking of, 174
 - donor site care and, 174
 - dressings for, 208, 210
 - for burn wounds, allografts, 209, 211
 - autografts, 172, 207, 210
 - nursing aspects of, 174
 - survival of, 172-173
 - types of, 172
 - uses of, 172-173
- Skin substitutes, for burn wound, 211-212
- Sleep. *See Sleep promotion.*
 - in young adult, characteristics of, 39-41
 - normal and aging, 39-47
 - cardiovascular disease and, 41-43
 - chronic obstructive pulmonary disease and, 43-44
 - dementia and, 43
 - hospitalization in critical care and, 46-47
 - medication effects and, 44-45
 - nervous system changes and, 40-41
 - obstructive sleep apnea syndrome and, 44-46
 - pain and, 44
 - psychological illness and, 44
 - urinary frequency and, 44
- Sleep disorder(s), obstructive sleep apnea, 44-46
 - periodic limb movements of sleep, 46
- Sleep disturbance, in delirium, 54
- Sleep promotion. *See Sleep.*
 - in elderly patient, **39-52**
 - assessment of sleep and, 47
 - interventions for, 47-48
- Slow-stroke back massage (SSBM), for sleep promotion, 49
- Social death, in facial disfigurement, 191-192
- SSBM (slow-stroke back massage), for sleep promotion, 49
- Status epilepticus, in the elderly, 73
- Step down unit, lung volume reduction surgery patient and, CareMap system in, 340
- Sterotomy wounds, dehiscence of, 220-221
 - musculocutaneous flap closure of, 177
- Steroids, effect of, on emotional state, 248
- Stool impaction, diarrhea and fecal incontinence from, 34
- Stress, from physical restraint, 64
 - in elderly family members, of critically ill, 92-93
 - metabolism in, 159-160
 - sleep and, 44
- Stress urinary incontinence, 32
- Stroke, seizures following, 71-72
- Stroke volume, in IABP, diastolic augmentation decrease and, 475
 - in IABP patient with pharmacologic intervention, 400
- Subcutaneous tissue, 126
- Support, provision of, for elderly family member, 99-100
- SVR. *See Systemic vascular resistance (SVR).*
- Systemic inflammatory response syndrome (SIRS), in septic shock, 1
- Systemic vascular resistance (SVR), in IABP, diastolic augmentation decrease and, 475
 - in IABP patient with pharmacologic intervention, 400-401
- Systolic blood pressure, in intraaortic balloon pumping, 355
 - in intra-aortic balloon pumping, 355
- Tacrolimus. *See FK506 (tacrolimus).*
- Tension-time index (TTI), of myocardial oxygen consumption, 373
 - IABC and, 374
- Thermal injury. *See Burn wound.*
- Thrombosis, free flap graft failure and, 180
- Thrombotic plaque, dislodgment of, with IABP, 418
- Timing waveform analysis, **349-356**. *See Waveform analysis, timing of.*
- Tissue perfusion, promotion of, in traumatic wounding, 112
 - wound healing and, 119, 125-126, 134
- Tissue pH, in free flap graft monitoring, 180-181
- Tissue tolerance, to pressure ulcers, 427-428
- Tonic-clonic seizure, in the elderly, 73
- Tracheostomy. *See Minitracheostomy.*
- Treppe effect, 379
- Trimethoprim/sulfamethoxazole, following lung transplantation, 263
- TTI. *See Tension-time index (TTI).*
- Ulcer(s). *See Pressure ulcers.*
 - arterial, 127, 153
 - assessment and care of, 146, 153-155
 - classification of, 132-133
 - compression therapy for, 154-155
 - diabetic/neuropathic, 155
 - lower extremity, 152-155
 - venous, 127, 129
 - venous stasis, 153-154
- Undermining, for wound closure, direct, 170, 172
- Universal precautions, in home wound care, 221-222
- Urethral sphincter, in bladder function, 30-31
- Urinary catheter, in incontinence management, 26, 35-36
- Urinary frequency, sleep and, 44
- Urinary incontinence, acute/transient, 31-32
 - chronic, 32
 - continence and, physiology of, 29-31
 - management of, 35-36
 - pathophysiology of, 31-32
 - skin breakdown from, 26-27

- Valine, in immunonutrition, 163
- Valproic acid, for seizures, in the elderly, 74
- Vancomycin, following lung transplantation, 263
- Vascular resistance, peripheral and pulmonary, effect on pulmonary surgery outcome, 308-310
- Vascular status, of IABP patient with pharmacologic intervention, 400-401, 406
- Vasoactive therapy, in IABP patient, 393
- Vasoconstrictors, in IABP patient, 394
- Vasodilators, in IABP patient, 394
- blood pressure and titration of, 474
- Ventilation, mechanical, of lung transplantation patient, 240-241
- Ventilation perfusion, in the elderly, 11
- Ventilatory failure, weaning failure and, 12-13
- Visitation, facilitation of, for elderly family member, 97-98
- Vitamins, in nutrition support, 162, 164-165
- Waveform analysis, in current IABP practice, 481
- timing of, arterial pressure in, 349-351, 354
- balloon in, 353-354
- deflation and, 351-355
- diastolic augmentation and, 351
- gas in, 354
- inflation in, 351-352
- landmarks in, 349-351
- pressure in, 354-355
- White noise, for sleep promotion, 49
- Withdrawal, seizures following, 72
- Wound care, at home, 217-218
- cleansing in, 142-143
- debridement in, 143-148
- definition of, 133
- documentation of, 137
- dressings in, 148-152
- equipment and, 137
- historical perspective of, 217
- hospital-community interaction in, 220
- in hospital, 218
- cost of, 218-219
- infection rate and, 219
- nursing care hours and, 219
- outpatient, **217-233**
- dehiscence and, 220-221
- medical waste management in, 221-222
- practice implications of, 220-222
- protocol for arthroplasties, 221
- standards of practice in, 219-220
- universal precautions and, 221-222
- patient and planning of, 137
- physical and mental care of patient in, 134-135
- planning for, 137
- steps in, 133-134, 137, 142-152
- support surface in, therapeutic, 135-137
- Wound care products, for surgical incisions, closed, 141-142, 145
- open, 142, 145
- Wound care products to promote a healing environment, **141-158**
- Wound healing, and critical illness, **115-123**
- factors in, 118-122
- by primary intention, 115, 130, 170-172
- factors in, 131
- by secondary intention, 115, 170
- cytokines in, 116, 118
- ebb phase in, 109-110
- flow phase in, 110
- host risk factors and, 116, 122
- inflammation in, 108-109
- leukocyte function impairment and, 198
- malnutrition and, 198
- microvascular disease and, 197-198
- nutrients essential to, 161-162, 164-165
- phases of, 115-118, 130-131
- physiology of, 115-118
- proliferation in, 109
- protein deficiency and, 198
- remodeling in, 109
- surgical options in, **169-182**
- free flaps, 178-181
- indications for reconstruction and, 169-172
- musculocutaneous flaps, 176-178
- results, long-term, 181
- skin grafts, 172-176
- Wound(s). See *Pressure ulcers; Ulcer(s)*.
- acute. See *Body image*.
- body image and, 183-188
- deformities from, reactions to, 191-192
- nutritional needs and, **159-167**
- psychological consideration and, **183-193**
- surgical, 188-190
- traumatic, 190-191
- assessment of, **125-139**
- elements of, 133-134
- measurement in, 132
- tools for, 131-132
- burn. See *Burn wound*.
- healing of. See *Wound healing*.
- in arthroplasty, hip and knee, 221
- pathophysiology of, 126-130
- skin graft and flap closure of, 172-181. See *Flap graft(s); Skin graft(s)*.
- sternotomy, 177, 220-221
- surgical, dehiscence of, 140, 220-221
- draining, 219-220
- traumatic versus, 127
- traumatic, **107-113**
- management goals in, 111-112
- responses to, local, 107-110
- systemic, 109-111
- versus surgical, 107
- vascular, 127, 129, 132